OncoMatch/Clinical Trials/NCT07154745
A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
Is NCT07154745 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Pozelimab and Cemdisiran for paroxysmal nocturnal hemoglobinuria.
Treatment: Pozelimab · Cemdisiran — This study is researching a treatment combination with two experimental drugs called pozelimab and cemdisiran referred to as "study drugs". Researchers are looking for a better way to treat Paroxysmal Nocturnal Hemoglobinuria (PNH). The aim of the study is to see how well the pozelimab and cemdisiran combination works to lower hemolysis in participants whose PNH has been not well controlled even after taking other complement component 5 (C5) inhibitors, eculizumab/eculizumab biosimilar, ravulizumab or crovalimab. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs? * How much of the study drugs are in the blood at different times? * Whether the body makes antibodies against the study drug (which could make the study drugs not work as well or could lead to side effects)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Excluded: C5 mutation that is refractory to their current C5i treatment
Patients with a known or suspected C5 mutation that is refractory to their current C5i treatment as described in the protocol
Prior therapy
Must have received: C5 inhibitor (eculizumab, ravulizumab, crovalimab) — current
Currently treated with marketed eculizumab, ravulizumab, or crovalimab at the labeled dose for at least 6 months
Cannot have received: organ transplant
Receipt of an organ transplant
Cannot have received: bone marrow transplantation or other hematologic transplants
history of bone marrow transplantation or other hematologic transplants
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07154745 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior organ transplant, bone marrow transplantation or other hematologic transplants disqualifies patients from enrollment.
Are patients with C5 alterations eligible?
No. C5 mutation that is refractory to their current C5i treatment is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify